StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR - Free Report) in a research note published on Tuesday morning. The brokerage issued a sell rating on the stock.
InspireMD Stock Performance
NYSE NSPR traded down $0.02 during mid-day trading on Tuesday, reaching $2.25. 5,598 shares of the stock were exchanged, compared to its average volume of 35,904. The stock has a market capitalization of $52.79 million, a PE ratio of -2.08 and a beta of 0.84. InspireMD has a 1-year low of $0.96 and a 1-year high of $3.85. The business's fifty day simple moving average is $2.48 and its 200 day simple moving average is $2.73.
InspireMD (NYSE:NSPR - Get Free Report) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same period last year, the business posted ($0.60) EPS. On average, analysts anticipate that InspireMD will post -0.61 EPS for the current year.
Hedge Funds Weigh In On InspireMD
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. McKinley Carter Wealth Services Inc. acquired a new stake in shares of InspireMD during the fourth quarter worth $28,000. Renaissance Technologies LLC acquired a new position in InspireMD in the 2nd quarter worth about $36,000. Avestar Capital LLC acquired a new stake in InspireMD in the third quarter valued at approximately $65,000. Northern Trust Corp bought a new position in shares of InspireMD during the 4th quarter valued at $80,000. Finally, Marshall Wace LLP bought a new position in InspireMD during the second quarter valued at about $4,670,000. 44.78% of the stock is owned by institutional investors.
About InspireMD
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.
Featured Articles
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
